Evercore ISI Begins Coverage on Agilent Technologies (A)

Evercore ISI initiated coverage on shares of Agilent Technologies (NYSE:A) in a research note published on Wednesday, January 3rd. The firm issued an outperform rating and a $75.00 price objective on the medical research company’s stock.

Several other brokerages also recently commented on A. Zacks Investment Research raised shares of Agilent Technologies from a hold rating to a buy rating and set a $76.00 price objective on the stock in a research report on Tuesday, October 31st. Robert W. Baird reissued a buy rating and set a $70.00 price objective on shares of Agilent Technologies in a research report on Friday, October 20th. Cowen reaffirmed a hold rating and set a $70.00 price target on shares of Agilent Technologies in a report on Wednesday, November 22nd. Deutsche Bank set a $75.00 price target on shares of Agilent Technologies and gave the company a buy rating in a report on Tuesday, November 21st. Finally, JPMorgan Chase & Co. raised their price target on shares of Agilent Technologies to $75.00 and gave the company an overweight rating in a report on Tuesday, November 21st. Six analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The stock has a consensus rating of Buy and an average price target of $68.98.

Agilent Technologies (NYSE A) opened at $71.73 on Wednesday. The company has a debt-to-equity ratio of 0.37, a current ratio of 3.30 and a quick ratio of 2.85. The company has a market cap of $23,080.00, a price-to-earnings ratio of 34.32, a price-to-earnings-growth ratio of 2.14 and a beta of 1.28. Agilent Technologies has a 1-year low of $47.05 and a 1-year high of $72.33.

Agilent Technologies (NYSE:A) last issued its quarterly earnings results on Monday, November 20th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.62 by $0.05. The company had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.17 billion. Agilent Technologies had a net margin of 15.30% and a return on equity of 16.95%. Agilent Technologies’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same period last year, the business earned $0.59 EPS. sell-side analysts predict that Agilent Technologies will post 2.58 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, January 24th. Shareholders of record on Tuesday, January 2nd will be paid a dividend of $0.149 per share. This is a boost from Agilent Technologies’s previous quarterly dividend of $0.13. The ex-dividend date is Friday, December 29th. This represents a $0.60 dividend on an annualized basis and a yield of 0.83%. Agilent Technologies’s dividend payout ratio (DPR) is presently 28.71%.

In other news, CFO Didier Hirsch sold 12,964 shares of Agilent Technologies stock in a transaction that occurred on Wednesday, November 22nd. The shares were sold at an average price of $69.00, for a total transaction of $894,516.00. Following the sale, the chief financial officer now owns 184,851 shares in the company, valued at $12,754,719. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Michael R. Mcmullen sold 43,703 shares of Agilent Technologies stock in a transaction that occurred on Friday, January 5th. The shares were sold at an average price of $70.00, for a total transaction of $3,059,210.00. Following the sale, the chief executive officer now owns 302,837 shares in the company, valued at approximately $21,198,590. The disclosure for this sale can be found here. In the last quarter, insiders have sold 176,291 shares of company stock worth $12,245,920.

Hedge funds have recently bought and sold shares of the stock. Dupont Capital Management Corp purchased a new position in shares of Agilent Technologies in the third quarter valued at $101,000. Balentine LLC grew its holdings in shares of Agilent Technologies by 2.9% in the second quarter. Balentine LLC now owns 1,794 shares of the medical research company’s stock valued at $106,000 after purchasing an additional 50 shares in the last quarter. Sun Life Financial INC boosted its stake in Agilent Technologies by 26,144.4% during the second quarter. Sun Life Financial INC now owns 2,362 shares of the medical research company’s stock worth $140,000 after buying an additional 2,353 shares during the period. Acrospire Investment Management LLC boosted its stake in Agilent Technologies by 92.3% during the second quarter. Acrospire Investment Management LLC now owns 2,500 shares of the medical research company’s stock worth $148,000 after buying an additional 1,200 shares during the period. Finally, Fiduciary Trust Co. purchased a new position in Agilent Technologies during the second quarter worth $186,000.

TRADEMARK VIOLATION WARNING: This story was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another site, it was illegally copied and reposted in violation of international copyright laws. The original version of this story can be viewed at https://www.dispatchtribunal.com/2018/01/13/agilent-technologies-a-earns-outperform-rating-from-analysts-at-evercore-isi.html.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.

Analyst Recommendations for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply